Form D · Pharmaceuticals
SignalRX Pharmaceuticals, Inc
Cumming, GA · CIK 0001974464
Offering snapshot reported May 3, 2023 · SEC filing
- Reported sold
- $250K Offering amount: $485K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Sep 16, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 3, 2023 | Initial | $250,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-480707
Source: Form D, filed May 3, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Guillermo Morales | Director |
| Joel Wernick | Director |
| Matthew Williams | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2215 Pilgrim Mill Circle
Cumming, GA, 30041
Cumming, GA, 30041